$ZGNX closed @ 1.22 down 26.99% Brean Capital Rei
Post# of 22751
Posted On: 03/11/2015 11:45:12 PM
$ZGNX closed @ 1.22 down 26.99%
Brean Capital Reiterates Buy After Zogenix, Inc. Sells Painkiller
March 11, 2015 12:29 PM EDT by Kate George, Editor in Exclusively Published • Healthcare • Insights
In a research report issued on March 11, Brean Capital analyst Difei Yang reiterated a Buy rating on Zogenix, Inc. (NASDAQ:ZGNX) with a price target of $2.50. The rating comes after the pharmaceutical company announced the sale of Zohydro ER, a painkiller, and released a Q4 report in-line with expectations.
Yang applauded the sale because it will allow Zogenix to simplify their operations, reduce their “cash burn,” and refocus on research and development. He noted that Zohydro ER’s price is “reasonable… given the profile and history of the product.” Zohydro was sold for $100 million “in upfront consideration,” but Yang believes the painkiller will reach $75 million in revenue in 2016 or 2017.
Aside from the sale of Zohydro, Yang is optimistic about Zogenix’s orphan drug currently in development. Yang expects ZX008, used to treat Dravet syndrone, to earn “top-line results by H2 2016″ and noted that ZX008 already posted impressive results from a previous open label study. He added, “If ZX008 eventually leads to approval, we believe it is a commercial launch that Zogenix can successfully handle.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Difei Yang has a total average return of 11.1% and a 62.1% success rate. Yang has a 28.0% average return when recommending ZGNX, and is ranked #859 out of 3511 analysts.
ZGNX Chart
Brean Capital
Brean Capital Yang
ZGNX
Zogenix
Related Articles
ZGNX
Brean Capital Comments On Zogenix Following Symphony Health Prescription Data
ZGNX
UPDATE: Brean Capital Maintains Buy On Zogenix Following Zohydro ER FDA Approval
RMTI
Oppenheimer’s Ling Wang Expects Rockwell Medical Shares To Have Significant Upside
Biotech2
MLV Reiterates Buy On CNAT, GALT And GLMD As Gilead Acquires Phenex Program For NASH
Real-Time Email Alerts
Choose Stocks
Your Email
Brean Capital Reiterates Buy After Zogenix, Inc. Sells Painkiller
March 11, 2015 12:29 PM EDT by Kate George, Editor in Exclusively Published • Healthcare • Insights
In a research report issued on March 11, Brean Capital analyst Difei Yang reiterated a Buy rating on Zogenix, Inc. (NASDAQ:ZGNX) with a price target of $2.50. The rating comes after the pharmaceutical company announced the sale of Zohydro ER, a painkiller, and released a Q4 report in-line with expectations.
Yang applauded the sale because it will allow Zogenix to simplify their operations, reduce their “cash burn,” and refocus on research and development. He noted that Zohydro ER’s price is “reasonable… given the profile and history of the product.” Zohydro was sold for $100 million “in upfront consideration,” but Yang believes the painkiller will reach $75 million in revenue in 2016 or 2017.
Aside from the sale of Zohydro, Yang is optimistic about Zogenix’s orphan drug currently in development. Yang expects ZX008, used to treat Dravet syndrone, to earn “top-line results by H2 2016″ and noted that ZX008 already posted impressive results from a previous open label study. He added, “If ZX008 eventually leads to approval, we believe it is a commercial launch that Zogenix can successfully handle.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Difei Yang has a total average return of 11.1% and a 62.1% success rate. Yang has a 28.0% average return when recommending ZGNX, and is ranked #859 out of 3511 analysts.
ZGNX Chart
Brean Capital
Brean Capital Yang
ZGNX
Zogenix
Related Articles
ZGNX
Brean Capital Comments On Zogenix Following Symphony Health Prescription Data
ZGNX
UPDATE: Brean Capital Maintains Buy On Zogenix Following Zohydro ER FDA Approval
RMTI
Oppenheimer’s Ling Wang Expects Rockwell Medical Shares To Have Significant Upside
Biotech2
MLV Reiterates Buy On CNAT, GALT And GLMD As Gilead Acquires Phenex Program For NASH
Real-Time Email Alerts
Choose Stocks
Your Email
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼